| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CMDC.201800714 |
| P698 | PubMed publication ID | 30521698 |
| P50 | author | Hui Qiu | Q90307971 |
| P2093 | author name string | Federica Morandi | |
| Ariele Viacava Follis | |||
| Daigen Xu | |||
| Igor Mochalkin | |||
| Brian Sherer | |||
| Roland Grenningloh | |||
| Jared Head | |||
| Lesley Liu-Bujalski | |||
| Richard Caldwell | |||
| Theresa Johnson | |||
| Andrew Bender | |||
| Anna Gardberg | |||
| Andreas Goutopoulos | |||
| Reinaldo Jones | |||
| Justin Potnick | |||
| P2860 | cites work | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
| Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma | Q33587826 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase | Q34303128 | ||
| A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase | Q36288294 | ||
| Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders | Q38011765 | ||
| B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. | Q38124120 | ||
| Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor | Q38938436 | ||
| A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells | Q38944958 | ||
| Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans | Q39412429 | ||
| Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis | Q42791258 | ||
| Btk function in B cell development and response. | Q45939727 | ||
| Btk inhibition treats TLR7/IFN driven murine lupus. | Q50886199 | ||
| Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells. | Q54116270 | ||
| Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk | Q57067987 | ||
| Recent developments of small molecule chemical probes for fluorescence-based detection of human carbonic anhydrase II and IX | Q61910924 | ||
| Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit | Q91024080 | ||
| Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors | Q91651285 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 217-223 | |
| P577 | publication date | 2019-01-09 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Discovery of Affinity-Based Probes for Btk Occupancy Assays | |
| P478 | volume | 14 |
Search more.